DE69839943D1 - Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen - Google Patents

Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen

Info

Publication number
DE69839943D1
DE69839943D1 DE69839943T DE69839943T DE69839943D1 DE 69839943 D1 DE69839943 D1 DE 69839943D1 DE 69839943 T DE69839943 T DE 69839943T DE 69839943 T DE69839943 T DE 69839943T DE 69839943 D1 DE69839943 D1 DE 69839943D1
Authority
DE
Germany
Prior art keywords
inhibition
presenting cells
immunoactivity
antigen
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69839943T
Other languages
English (en)
Inventor
Warren D Shlomchik
Mark Jay Shlomchik
Stephen G Emerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
University of Pennsylvania Penn
Original Assignee
Yale University
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, University of Pennsylvania Penn filed Critical Yale University
Application granted granted Critical
Publication of DE69839943D1 publication Critical patent/DE69839943D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69839943T 1997-11-12 1998-11-12 Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen Expired - Fee Related DE69839943D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6519897P 1997-11-12 1997-11-12
PCT/US1998/024183 WO1999024078A1 (en) 1997-11-12 1998-11-12 Prevention of immunoreactivity by depleting or inhibiting antigen presenting cells

Publications (1)

Publication Number Publication Date
DE69839943D1 true DE69839943D1 (de) 2008-10-09

Family

ID=22061000

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839943T Expired - Fee Related DE69839943D1 (de) 1997-11-12 1998-11-12 Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen

Country Status (6)

Country Link
US (1) US7288255B1 (de)
EP (1) EP1028754B1 (de)
AT (1) ATE406178T1 (de)
AU (1) AU754764B2 (de)
DE (1) DE69839943D1 (de)
WO (1) WO1999024078A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324199A1 (en) 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
AU2002218019A1 (en) * 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
AU2016246707B2 (en) 2015-04-06 2021-03-25 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
EA039364B1 (ru) * 2015-10-09 2022-01-18 Президент Энд Феллоус Оф Гарвард Колледж Композиции и способы для немиелоаблативного кондиционирования
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11273179B2 (en) 2018-03-12 2022-03-15 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239062A (en) * 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
GB9117522D0 (en) * 1991-08-14 1991-10-02 Medical Res Council Ligands for dendritic cells, their uses and production

Also Published As

Publication number Publication date
AU1584999A (en) 1999-05-31
US7288255B1 (en) 2007-10-30
WO1999024078A1 (en) 1999-05-20
EP1028754A1 (de) 2000-08-23
EP1028754B1 (de) 2008-08-27
EP1028754A4 (de) 2002-11-27
ATE406178T1 (de) 2008-09-15
AU754764B2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
PT1032662E (pt) Metodos e composicoes para imunomodulacao.
IL189629A0 (en) Compositions containing human ctla-4 antibodies
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
NO982062D0 (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
EA200100822A1 (ru) Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
BR9707819A (pt) Imunogenos peptidicos
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DE69435303D1 (de) Er behandlung von krankheiten bei denen eine cytok
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
HUP0001458A2 (hu) Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase
AU7079300A (en) Compositions and methods for the treatment of immune related diseases
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
WO2002094184A3 (en) Vaccines for the treatment of autoimmune disease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee